Skip Nav Destination
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
Issue Archive
Table of Contents
INSIDE BLOOD
REVIEW ARTICLES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
Clinical Trials & Observations
Ghada Kchour,Mahdi Tarhini,Mohamad-Mehdi Kooshyar,Hiba El Hajj,Eric Wattel,Mahmoud Mahmoudi,Hassan Hatoum,Hossein Rahimi,Masoud Maleki,Houshang Rafatpanah,S. A. Rahim Rezaee,Mojtaba Tabatabaei Yazdi,Abbas Shirdel,Hugues de Thé,Olivier Hermine,Reza Farid,Ali Bazarbachi
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
Clinical Trials & Observations
Azra Raza,Naomi Galili,Scott Smith,John Godwin,Jeffrey Lancet,Magda Melchert,Marsha Jones,James G. Keck,Lisa Meng,Gail L. Brown,Alan List
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Clinical Trials & Observations
Ulrich Keilholz,Anne Letsch,Antonia Busse,Anne Marie Asemissen,Sandra Bauer,Igor Wolfgang Blau,Wolf-Karsten Hofmann,Lutz Uharek,Eckhard Thiel,Carmen Scheibenbogen
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Clinical Trials & Observations
Phoenix A. Ho,Todd A. Alonzo,Robert B. Gerbing,Jessica Pollard,Derek L. Stirewalt,Craig Hurwitz,Nyla A. Heerema,Betsy Hirsch,Susana C. Raimondi,Beverly Lange,Janet L. Franklin,Jerald P. Radich,Soheil Meshinchi
Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Brief Report
Stephan Metzelder,Ying Wang,Ellen Wollmer,Michael Wanzel,Sabine Teichler,Anuhar Chaturvedi,Martin Eilers,Erich Enghofer,Andreas Neubauer,Andreas Burchert
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
Brief Report
Bijay Nair,John D. Shaughnessy, Jr,Yiming Zhou,Marie Astrid-Cartron,Pingping Qu,Frits van Rhee,Elias Anaissie,Yazan Alsayed,Sarah Waheed,Klaus Hollmig,Jackie Szymonifka,Nathan Petty,Antje Hoering,Bart Barlogie
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells
Sian M. Henson,Ornella Franzese,Richard Macaulay,Valentina Libri,Rita I. Azevedo,Sorena Kiani-Alikhan,Fiona J. Plunkett,Joanne E. Masters,Sarah Jackson,Stephen J. Griffiths,Hans-Peter Pircher,Maria V. D. Soares,Arne N. Akbar
LYMPHOID NEOPLASIA
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Aldo M. Roccaro,Antonio Sacco,Brian Thompson,Xavier Leleu,Abdel Kareem Azab,Feda Azab,Judith Runnels,Xiaoying Jia,Hai T. Ngo,Molly R. Melhem,Charles P. Lin,Domenico Ribatti,Barrett J. Rollins,Thomas E. Witzig,Kenneth C. Anderson,Irene M. Ghobrial
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin
Paul Robach,Stefania Recalcati,Domenico Girelli,Cecilia Gelfi,Niels J. Aachmann-Andersen,Jonas J. Thomsen,Anne M. Norgaard,Alessandra Alberghini,Natascia Campostrini,Annalisa Castagna,Agnese Viganò,Paolo Santambrogio,Tibor Kempf,Kai C. Wollert,Stéphane Moutereau,Carsten Lundby,Gaetano Cairo
VASCULAR BIOLOGY
-
Cover Image
Cover Image
![issue cover]()
Transformed (ImageJ) and pseudocolored (Adobe Photoshop) image of a human endothelial progenitor-derived colony consisting of 1764 cells (as counted automatically by using the “Analyze Particles...” feature within the ImageJ image processing program developed at the National Institutes of Health: http://rsbweb.nih.gov/ij/). One endothelial colony-forming cell (ECFC) produced that progeny through 10.78 calculated population doublings (210 + 1024) within 10 days. See the article by Reinisch et al on page 6716..
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
